SlideShare a Scribd company logo
What we need to know about CDISC

Shannon Labout, CCDM
Director, Data Management
WHAT WE NEED TO KNOW ABOUT CDISC

 What are the CDISC standards?
 What is the best timing to implement CDISC
  standards in a clinical program?
 What is the timeline for requiring CDISC
  Standards in FDA Submissions?
WHAT ARE THE CDISC STANDARDS

 CDISC organized as a non-profit standards
  developing organization (SDO) in 2000
 CDISC works closely with other SDOs (e.g.,
  HL7, ISO) and with the FDA
 CDISC develops standards for medical
  research (started with volunteers in 1990s)
 CDISC standards development is an open,
  consensus-based process, powered by
  volunteers
 www.CDISC.org
http://www.cdisc.org/foundation-standards
TIMING OF IMPLEMENTATION MATTERS!

1. If you choose to convert your legacy data
   to SDTM at the end of the process
   Allows you to hold on to your old processes
     and standards
   But…
   Adds significant time, effort, and expense at
     the end of the process
   Legacy data conversion can introduce other
     significant problems
LEGACY DATA CONVERSION PROBLEMS

 No 1:1 relationship between CRF and SDTM
  domains/variables means you will have to
  spend a lot of time mapping data to the
  right domains/variables
 Collected values may not map to controlled
  terminologies that are required
 No standards definitions/assumptions make
  the data less “combinable” – may not be
  able to map with the same meaning
TIMING OF IMPLEMENTATION MATTERS!
2.   Streamline your processes by building (industry)
     standards into your process up-front:
      Saves time, money, effort
          Automatically generate deliverables throughout
          Build a standard library of CRFs, database structures,
           SAS programming, etc.
          Reduce (or eliminates) mapping and re-programming
           throughout the process
      Makes data more combinable, re-usable
      Allows data sharing with vendors and other research
       partners more easily
      Supports FDA objectives
          Standard format for data submissions and data
           repository
          Builds in transparency and traceability
IMPLEMENT STANDARDS FROM THE START
 ODM – designed to hold CDISC content plus
  audit trail, based on XML
 PRM – structured protocol information makes it
  reusable downstream (registries, EDC, CSR,
  labeling), based on XML
 CDASH – standard metadata for CRFs is
  harmonized with other CDISC standards –
  makes it easier to get to SDTM and ADaM
 Controlled terminologies with standard
  definitions
    Everyone collecting the same information the
     same way makes that data more usable and
     meaningful in a data repository
WILL CDISC STANDARDS BE REQUIRED?
             Two Perspectives
YES! CDISC STANDARDS WILL BE REQUIRED




      Supporting the Vision, Innovation and Opportunity
                of the Critical Path Initiative
YES!! CDISC STANDARDS WILL BE REQUIRED
Whichever way we choose to look at it…

CDISC STANDARDS ARE NO
LONGER OPTIONAL FOR FDA
SUBMISSIONS
2004
Critical Path
 Initiative
http://www.fda.gov/ScienceResearch/SpecialT
opics/CriticalPathInitiative/CriticalPathOpport
unitiesReports/ucm077262.htm
CRITICAL PATH INITIATIVE

 The Critical Path Initiative (CPI) is FDA's
  national strategy to drive innovation in the
  scientific processes through which
  medical products are developed,
  evaluated, and manufactured.




 FDA was hoping that industry would
  voluntarily adopt standards…
2004 Critical   2006 Federal
    Path          Register
  Initiative      Notice
FEDERAL REGISTER NOTICE

 In 2006, FDA told us the requirement was
  coming
   all submissions to be electronic
   all submissions to follow standard formats
    (e.g., SDTM)
 They were still hoping we would voluntarily
  adopt standards…
2004        2006       2008       2010
 Critical    Federal    Federal    Federal
  Path       Register   Register   Register
Initiative   Notice     Notice     Notice
WHAT’S HAPPENED SINCE THEN?

 ARRA $$ invested in FDA’s standards
  implementation
 CDER Computational Science Center
 Cross-Center FDA Data Standards Council
 New Software and Tools
 New Review Environment
 Janus V1, V2, V3
 CDISC training developed for FDA
  reviewers
 CDISC Standards are being built in at FDA
FDASIA INTRODUCES THE REQUIREMENT




          2012
       FDASIA and
        PDUFA V
FDASIA

 Food and Drug Administration Safety and
  Innovation Act of 2012
  Signed into law July 2012
  Became effective October 2012
  a few key points
     Reauthorizes PDUFA and MDUFA
     Creates User Fees for Biosimilars and
      Generics
     Section 1136 requires electronic
      submissions in a standard format to be
      referenced in binding Guidance
PDUFA V IT PLAN

Objective
“FDA is committed to achieve the long-term
  goal of improving the exchange, review,
  and management of human drug and
  biologic applications throughout the product
  life cycle through strategic investments in
  automated, standards-based information
  technology (IT).”
BINDING GUIDANCE

FDA will issue final guidance no later than 12
  months from the close of the public comment
  period on the draft guidance. Such final
  guidance and any subsequent revisions to
  the final guidance shall be binding on
  sponsors, applicants, and manufacturers no
  earlier than twenty-four months after
  issuance of the final guidance.
DRAFT GUIDANCE ISSUED 2012
      Harmonized cross-center
         CDER – Drug applications
         CBER – Biologics applications
         CDRH – Device / Radiological applications
      Specifies the requirement for electronic submission in
       a standard format
      FDA publishes the standard formats they will accept
       on their data standards web page
         References these CDISC standards
               SDTM - tabulations of collected data
               Controlled Terminology – allowed values
               ADaM – analysis datasets (supports CSR)
               SEND – pre-clinical data (based on SDTM)
               Define.xml – standard metadata format
http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm
FREE WEBINAR “CDISC WILL BE REQUIRED!”
AVAILABLE ONLINE AT
HTTP://KESTRELCONSULTING.TRAININGCAMPUS.NET
DEVELOPING TA STANDARDS

 FDA has published intent to help industry create
  therapeutic area (TA) specific standards by
  2017 (PDUFA V commitment letter)
 High priority therapeutic areas published on
  FDA website
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Form
    sSubmissionRequirements/ElectronicSubmissions/ucm287408.h
                          tm#_ftnref10)
 Working with CDISC and others to develop TA
 Standards development open to all who can
  participate (http://www.cdisc.org/therapeutic)
FDA Timeline




 This assumes standardization projects for therapeutic areas would be scoped narrowly enough
to be accomplishable within a 12-month period, and that subsequent projects in those areas
would build on the results.
CDISC Timeline
HOW WE CAN STAY UP TO DATE
 Monthly CDISC webinars
   Updates on what’s being released for public
    review – new domains, new terminology, etc
   Free to attend live webinar
   Archives are available on demand to CDISC
    members
 CDISC Newsletter (monthly, free)
 CDISC website (www.cdisc.org)
 CDISC Education & Events
   Private and public courses
   Conferences (Interchange) in US, EU and AP
RESOURCES
 www.cdisc.org/foundational-standards - Starting
  point for all the standards
 http://www.cdisc.org/content6283 - Technical
  development plan (Gantt chart)

 http://www.fda.gov/ForIndustry/DataStandards/
  StudyDataStandards/default.htm
    Email accounts for questions
     (cber.cdisc@fda.hhs.gov, cder-edata@fda.hhs.gov,
     cdrh.cdisc@fda.hhs.gov)
 http://www.opencdisc.org/
    Validation of your submission
    Help with Define.xml
TAKE AWAY MESSAGES

 It’s time to implement CDISC standards - no
  longer optional for FDA submissions
   Right now – FDA wants SDTM/ADaM
   In the near future – FDA will require
    SDTM/ADaM
 Update / improve your processes to take
  full advantage of these industry standards
 Get involved with standards development
   Contribute your TA-specific knowledge
   Help develop the standards we all will have
    to use
THANK YOU!
  Shannon Labout, CCDM
Director, Data Management
  slabout@sdcclinical.com

More Related Content

PPT
CDISC SDTM Domain Presentation
PPTX
ADaM - Where Do I Start?
PPTX
Metadata and ADaM
PPTX
Presentation on CDISC- SDTM guidelines.
PPT
Trial Design Domains
PPTX
SDTM (Study Data Tabulation Model)
PPTX
Introduction to SDTM
PDF
CDISC-CDASH
CDISC SDTM Domain Presentation
ADaM - Where Do I Start?
Metadata and ADaM
Presentation on CDISC- SDTM guidelines.
Trial Design Domains
SDTM (Study Data Tabulation Model)
Introduction to SDTM
CDISC-CDASH

What's hot (20)

PDF
Data management plan (important components and best practices) final v 1.0
PPT
define_xml_tutorial .ppt
PPTX
Clinical Data Management Process Overview_Katalyst HLS
PDF
Why ADaM for a statistician?
PPTX
SDTM Fnal Detail Training
PPT
SDTM - Adverse Events Vs. Clinical Events
PPTX
Clinical Data Management Plan_Katalyst HLS
PDF
CDISC's CDASH and SDTM: Why You Need Both!
PDF
Cdisc sdtm implementation_process _v1
PPT
CLINICAL DATA MANGEMENT (CDM)
PDF
How to build ADaM BDS dataset from mock up table
PDF
Handling Third Party Vendor Data_Katalyst HLS
PDF
INTERPRETING CDISC ADaM IG THROUGH USERS INTERPRETATION
PDF
Study start up activities in clinical data management
PPTX
Study setup_Clinical Data Management_Katalyst HLS
PPTX
A Systematic Review of ADaM IG Interpretation
PPTX
Case Report Form (CRF)
PDF
Database Lock _ Unlock Procedure_Katalyst HLS
PPTX
Database Designing in Clinical Data Management
Data management plan (important components and best practices) final v 1.0
define_xml_tutorial .ppt
Clinical Data Management Process Overview_Katalyst HLS
Why ADaM for a statistician?
SDTM Fnal Detail Training
SDTM - Adverse Events Vs. Clinical Events
Clinical Data Management Plan_Katalyst HLS
CDISC's CDASH and SDTM: Why You Need Both!
Cdisc sdtm implementation_process _v1
CLINICAL DATA MANGEMENT (CDM)
How to build ADaM BDS dataset from mock up table
Handling Third Party Vendor Data_Katalyst HLS
INTERPRETING CDISC ADaM IG THROUGH USERS INTERPRETATION
Study start up activities in clinical data management
Study setup_Clinical Data Management_Katalyst HLS
A Systematic Review of ADaM IG Interpretation
Case Report Form (CRF)
Database Lock _ Unlock Procedure_Katalyst HLS
Database Designing in Clinical Data Management
Ad

Similar to What We Need to Know About CDISC (20)

PDF
Strategies for Implementing CDISC
PDF
Development_data_standards_data_integration_tools
PDF
Importance of data standards and system validation of software for clinical r...
PDF
Invite Event: CDISC Standards from Study Design to Analysis, June 13, Paris-FR
DOCX
Clinical data management
PPTX
Standards Metadata Management (system)
PPTX
effective data sharing for a learning healthcare system
PPTX
Clinical data management
DOC
PROJECT softwares (28 May 14)
PPTX
Post-lock Data Flow: From CRF to FDA
PDF
Are you ready for Dec 17, 2016 - CDISC compliant data?
PPTX
CDISC Electronic Submission to FDA
PDF
Evaluation of the importance of standards for data and metadata exchange for ...
PPTX
regulatory.pptx
PPTX
Clinical Data Management, Clinical research, clinical trial
PPTX
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
PPTX
Beyond regulatory submission - standards metadata management
PDF
2015 DIA China
PDF
Automated clinical documentation improvement
PDF
Data Management in Clinical Research
Strategies for Implementing CDISC
Development_data_standards_data_integration_tools
Importance of data standards and system validation of software for clinical r...
Invite Event: CDISC Standards from Study Design to Analysis, June 13, Paris-FR
Clinical data management
Standards Metadata Management (system)
effective data sharing for a learning healthcare system
Clinical data management
PROJECT softwares (28 May 14)
Post-lock Data Flow: From CRF to FDA
Are you ready for Dec 17, 2016 - CDISC compliant data?
CDISC Electronic Submission to FDA
Evaluation of the importance of standards for data and metadata exchange for ...
regulatory.pptx
Clinical Data Management, Clinical research, clinical trial
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
Beyond regulatory submission - standards metadata management
2015 DIA China
Automated clinical documentation improvement
Data Management in Clinical Research
Ad

More from Statistics & Data Corporation (12)

PPTX
Handling of Missing Data in Clinical Trials for Non-Statisticians
PPTX
Webinar | Site Relationships: Why They Matter and How to Foster Them 1-31-17
PPTX
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
PPTX
Understanding Statistical Power for Non-Statisticians
PDF
A Mixed Model, Repeated Measure Analysis of Demographics and Dry Eye Signs an...
PDF
iMedNet EDC Maximizes eClinical Development Process Efficiency
PDF
ARVO 2015 Poster Presentation by Kirk Bateman, Director, Biostatistics
PDF
Retina Today (Nov-Dec 2014): The Clinical Data Management Process
PDF
"Efficacy and Safety of Treatment with an Anti‐M2e Monoclonal Antibody in Exp...
PDF
Shannon Labout Presenting at MAGI Clinical Research Conference - Las Vegas, 2...
PDF
SDC Booth June 2013
PDF
SDTM and CDASH Training with Shannon Labout
Handling of Missing Data in Clinical Trials for Non-Statisticians
Webinar | Site Relationships: Why They Matter and How to Foster Them 1-31-17
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
Understanding Statistical Power for Non-Statisticians
A Mixed Model, Repeated Measure Analysis of Demographics and Dry Eye Signs an...
iMedNet EDC Maximizes eClinical Development Process Efficiency
ARVO 2015 Poster Presentation by Kirk Bateman, Director, Biostatistics
Retina Today (Nov-Dec 2014): The Clinical Data Management Process
"Efficacy and Safety of Treatment with an Anti‐M2e Monoclonal Antibody in Exp...
Shannon Labout Presenting at MAGI Clinical Research Conference - Las Vegas, 2...
SDC Booth June 2013
SDTM and CDASH Training with Shannon Labout

Recently uploaded (20)

PPTX
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
PPT
Infections Member of Royal College of Physicians.ppt
PPTX
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
PPTX
Post Op complications in general surgery
PPTX
2 neonat neotnatology dr hussein neonatologist
PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
PDF
Transcultural that can help you someday.
PPTX
antibiotics rational use of antibiotics.pptx
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPTX
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
PPT
Rheumatology Member of Royal College of Physicians.ppt
PPTX
CHEM421 - Biochemistry (Chapter 1 - Introduction)
PDF
Cardiology Pearls for Primary Care Providers
PPTX
Electrolyte Disturbance in Paediatric - Nitthi.pptx
PPTX
Neuropathic pain.ppt treatment managment
PPTX
regulatory aspects for Bulk manufacturing
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PPTX
Anatomy and physiology of the digestive system
PDF
Copy of OB - Exam #2 Study Guide. pdf
PDF
Extended-Expanded-role-of-Nurses.pdf is a key for student Nurses
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
Infections Member of Royal College of Physicians.ppt
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
Post Op complications in general surgery
2 neonat neotnatology dr hussein neonatologist
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
Transcultural that can help you someday.
antibiotics rational use of antibiotics.pptx
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
Rheumatology Member of Royal College of Physicians.ppt
CHEM421 - Biochemistry (Chapter 1 - Introduction)
Cardiology Pearls for Primary Care Providers
Electrolyte Disturbance in Paediatric - Nitthi.pptx
Neuropathic pain.ppt treatment managment
regulatory aspects for Bulk manufacturing
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
Anatomy and physiology of the digestive system
Copy of OB - Exam #2 Study Guide. pdf
Extended-Expanded-role-of-Nurses.pdf is a key for student Nurses

What We Need to Know About CDISC

  • 1. What we need to know about CDISC Shannon Labout, CCDM Director, Data Management
  • 2. WHAT WE NEED TO KNOW ABOUT CDISC  What are the CDISC standards?  What is the best timing to implement CDISC standards in a clinical program?  What is the timeline for requiring CDISC Standards in FDA Submissions?
  • 3. WHAT ARE THE CDISC STANDARDS  CDISC organized as a non-profit standards developing organization (SDO) in 2000  CDISC works closely with other SDOs (e.g., HL7, ISO) and with the FDA  CDISC develops standards for medical research (started with volunteers in 1990s)  CDISC standards development is an open, consensus-based process, powered by volunteers  www.CDISC.org
  • 5. TIMING OF IMPLEMENTATION MATTERS! 1. If you choose to convert your legacy data to SDTM at the end of the process Allows you to hold on to your old processes and standards But… Adds significant time, effort, and expense at the end of the process Legacy data conversion can introduce other significant problems
  • 6. LEGACY DATA CONVERSION PROBLEMS  No 1:1 relationship between CRF and SDTM domains/variables means you will have to spend a lot of time mapping data to the right domains/variables  Collected values may not map to controlled terminologies that are required  No standards definitions/assumptions make the data less “combinable” – may not be able to map with the same meaning
  • 7. TIMING OF IMPLEMENTATION MATTERS! 2. Streamline your processes by building (industry) standards into your process up-front:  Saves time, money, effort  Automatically generate deliverables throughout  Build a standard library of CRFs, database structures, SAS programming, etc.  Reduce (or eliminates) mapping and re-programming throughout the process  Makes data more combinable, re-usable  Allows data sharing with vendors and other research partners more easily  Supports FDA objectives  Standard format for data submissions and data repository  Builds in transparency and traceability
  • 8. IMPLEMENT STANDARDS FROM THE START  ODM – designed to hold CDISC content plus audit trail, based on XML  PRM – structured protocol information makes it reusable downstream (registries, EDC, CSR, labeling), based on XML  CDASH – standard metadata for CRFs is harmonized with other CDISC standards – makes it easier to get to SDTM and ADaM  Controlled terminologies with standard definitions  Everyone collecting the same information the same way makes that data more usable and meaningful in a data repository
  • 9. WILL CDISC STANDARDS BE REQUIRED? Two Perspectives
  • 10. YES! CDISC STANDARDS WILL BE REQUIRED Supporting the Vision, Innovation and Opportunity of the Critical Path Initiative
  • 11. YES!! CDISC STANDARDS WILL BE REQUIRED
  • 12. Whichever way we choose to look at it… CDISC STANDARDS ARE NO LONGER OPTIONAL FOR FDA SUBMISSIONS
  • 15. CRITICAL PATH INITIATIVE  The Critical Path Initiative (CPI) is FDA's national strategy to drive innovation in the scientific processes through which medical products are developed, evaluated, and manufactured.  FDA was hoping that industry would voluntarily adopt standards…
  • 16. 2004 Critical 2006 Federal Path Register Initiative Notice
  • 17. FEDERAL REGISTER NOTICE  In 2006, FDA told us the requirement was coming all submissions to be electronic all submissions to follow standard formats (e.g., SDTM)  They were still hoping we would voluntarily adopt standards…
  • 18. 2004 2006 2008 2010 Critical Federal Federal Federal Path Register Register Register Initiative Notice Notice Notice
  • 19. WHAT’S HAPPENED SINCE THEN?  ARRA $$ invested in FDA’s standards implementation  CDER Computational Science Center  Cross-Center FDA Data Standards Council  New Software and Tools  New Review Environment  Janus V1, V2, V3  CDISC training developed for FDA reviewers  CDISC Standards are being built in at FDA
  • 20. FDASIA INTRODUCES THE REQUIREMENT 2012 FDASIA and PDUFA V
  • 21. FDASIA  Food and Drug Administration Safety and Innovation Act of 2012 Signed into law July 2012 Became effective October 2012 a few key points Reauthorizes PDUFA and MDUFA Creates User Fees for Biosimilars and Generics Section 1136 requires electronic submissions in a standard format to be referenced in binding Guidance
  • 22. PDUFA V IT PLAN Objective “FDA is committed to achieve the long-term goal of improving the exchange, review, and management of human drug and biologic applications throughout the product life cycle through strategic investments in automated, standards-based information technology (IT).”
  • 23. BINDING GUIDANCE FDA will issue final guidance no later than 12 months from the close of the public comment period on the draft guidance. Such final guidance and any subsequent revisions to the final guidance shall be binding on sponsors, applicants, and manufacturers no earlier than twenty-four months after issuance of the final guidance.
  • 24. DRAFT GUIDANCE ISSUED 2012  Harmonized cross-center  CDER – Drug applications  CBER – Biologics applications  CDRH – Device / Radiological applications  Specifies the requirement for electronic submission in a standard format  FDA publishes the standard formats they will accept on their data standards web page  References these CDISC standards  SDTM - tabulations of collected data  Controlled Terminology – allowed values  ADaM – analysis datasets (supports CSR)  SEND – pre-clinical data (based on SDTM)  Define.xml – standard metadata format http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm
  • 25. FREE WEBINAR “CDISC WILL BE REQUIRED!” AVAILABLE ONLINE AT HTTP://KESTRELCONSULTING.TRAININGCAMPUS.NET
  • 26. DEVELOPING TA STANDARDS  FDA has published intent to help industry create therapeutic area (TA) specific standards by 2017 (PDUFA V commitment letter)  High priority therapeutic areas published on FDA website (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Form sSubmissionRequirements/ElectronicSubmissions/ucm287408.h tm#_ftnref10)  Working with CDISC and others to develop TA  Standards development open to all who can participate (http://www.cdisc.org/therapeutic)
  • 27. FDA Timeline This assumes standardization projects for therapeutic areas would be scoped narrowly enough to be accomplishable within a 12-month period, and that subsequent projects in those areas would build on the results.
  • 29. HOW WE CAN STAY UP TO DATE  Monthly CDISC webinars Updates on what’s being released for public review – new domains, new terminology, etc Free to attend live webinar Archives are available on demand to CDISC members  CDISC Newsletter (monthly, free)  CDISC website (www.cdisc.org)  CDISC Education & Events Private and public courses Conferences (Interchange) in US, EU and AP
  • 30. RESOURCES  www.cdisc.org/foundational-standards - Starting point for all the standards  http://www.cdisc.org/content6283 - Technical development plan (Gantt chart)  http://www.fda.gov/ForIndustry/DataStandards/ StudyDataStandards/default.htm  Email accounts for questions (cber.cdisc@fda.hhs.gov, cder-edata@fda.hhs.gov, cdrh.cdisc@fda.hhs.gov)  http://www.opencdisc.org/  Validation of your submission  Help with Define.xml
  • 31. TAKE AWAY MESSAGES  It’s time to implement CDISC standards - no longer optional for FDA submissions Right now – FDA wants SDTM/ADaM In the near future – FDA will require SDTM/ADaM  Update / improve your processes to take full advantage of these industry standards  Get involved with standards development Contribute your TA-specific knowledge Help develop the standards we all will have to use
  • 32. THANK YOU! Shannon Labout, CCDM Director, Data Management slabout@sdcclinical.com